Comparative Bioequivalence Study of 2 Clopidogrel 75-mg Tablet Formulations in Moroccan Volunteers

Clin Pharmacol Drug Dev. 2024 Sep;13(9):1044-1050. doi: 10.1002/cpdd.1442. Epub 2024 Jun 26.

Abstract

This study investigates the pharmacokinetic properties and bioequivalence of 2 formulations of clopidogrel tablets administered to a cohort of healthy Moroccan male volunteers. The primary objective was to assess the rate and extent of drug absorption from the test formulation in comparison to a reference formulation, focusing on critical parameters including maximum plasma concentration (Cmax), area under the concentration-time curve from 0 to the last measurable time (AUC0-t), and area under the concentration-time curve extrapolated to infinity (AUC0-∞). The results revealed that the geometric mean ratios of Cmax, AUC0-t, and AUC0-∞ for the test formulation relative to the reference formulation were 105.7%, 105.6%, and 105.6%, respectively. The 90% confidence intervals for these parameters fell within the predefined bioequivalence range of 80%-125%, indicating a statistically and clinically equivalent performance between the 2 formulations. This investigation sheds light on the pharmacokinetic behavior of clopidogrel in the context of the Moroccan male population, offering valuable insights into the comparability of formulations.

Keywords: Moroccan volunteers; bioequivalence; clopidogrel; pharmacokinetics.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Area Under Curve*
  • Clopidogrel* / administration & dosage
  • Clopidogrel* / pharmacokinetics
  • Cross-Over Studies*
  • Healthy Volunteers
  • Humans
  • Male
  • Morocco
  • Platelet Aggregation Inhibitors* / administration & dosage
  • Platelet Aggregation Inhibitors* / pharmacokinetics
  • Tablets*
  • Therapeutic Equivalency*
  • Young Adult

Substances

  • Clopidogrel
  • Tablets
  • Platelet Aggregation Inhibitors